Comparison tool

Glow Protocol vs GHK-Cu side-by-side

Stack up to four peptides by evidence status, mechanisms, study dosing, side effects, and references.

Selected (2/4)

Glow ProtocolGHK-Cu

Share this peptide comparison

Property	Glow Protocol	GHK-Cu
Category	Peptide Blend	Skin & Hair
Also known as	Glow Stack, Glow Blend, Skin Rejuvenation Stack	Copper Peptide, Glycyl-L-histidyl-L-lysine copper
FDA approved	No	No
Clinical status	Preclinical Research (Components) Pre Preclinical I Phase I II Phase II III Phase III IV Phase IV FDA FDA approved	Used in cosmetic products with limited human topical-skincare evidence; the source also notes injectable compounding restrictions and a pending reclassification process. Pre Preclinical I Phase I II Phase II III Phase III IV Phase IV FDA FDA approved
What to expect	Skin rejuvenation, anti-aging, collagen production	Skin rejuvenation, wound healing, hair growth, anti-aging
How it works	Glow Protocol is described as a three-component peptide blend. GHK-Cu is the copper-binding tripeptide in the stack and is linked in the source to collagen, elastin, glycosaminoglycan production, matrix metalloproteinase modulation, and angiogenesis signals from cell and animal evidence. BPC-157 is included for proposed pro-healing and anti-inflammatory activity tied to angiogenesis and growth-factor signaling in rodent studies. TB-500 is described as an actin-binding thymosin beta-4 fragment included for cell migration and tissue-remodeling hypotheses. The source explicitly frames the combined mechanism as plausible extrapolation rather than proof that the injectable blend works as a unified product.	GHK-Cu is described as the copper(II) complex of the GHK tripeptide. The source connects its activity to copper binding and possible cellular copper delivery, but also emphasizes effects that go beyond a simple carrier model. Reported laboratory observations include shifts in gene expression, increased fibroblast production of extracellular-matrix components, keratinocyte support, vascular-related activity, and antioxidant or anti-inflammatory signals. The precise mechanism is still not fully defined.
Typical dosing	Standard vial dosing per protocol · Once daily	1-2 mg daily injection or 0.05% topical · Once daily · Subcutaneous injection or topical application
Research dosing	5:1:1 ratio GHK-Cu:TB-500:BPC-157 · 8-12 weeks for visible results · Subcutaneous injection	1-2 mg for injectable protocols · Varies by application · Subcutaneous injection or topical application
Typical duration	8-12 weeks for visible results	Varies by application
Administration	Subcutaneous injection	Subcutaneous injection or topical application
Timing	Evening With or without food	Evening for skin or recovery contexts With or without food
Evidence level	Preclinical	Clinical Trials
Possible side effects	Injection site reactions Temporary skin flushing Mild headache (Reported as rare in the source.) +1 more Fatigue during initial use	Generally well tolerated (Reported as a general tolerability statement in the source.) Mild topical irritation, redness, or tingling (Associated with topical use.) Injection-site reactions (Associated with injectable use.) +4 more Possible histamine release (Source advises caution for MCAS or histamine sensitivity.) Copper toxicity risk with excessive use (Risk described for excessive exposure.) Wilson's disease contraindication (Source lists Wilson's disease as contraindicated.) Caution with active cancer (Source flags an angiogenesis-related concern.)
Research summary	The source distinguishes the evidence for the ingredients. GHK-Cu is described as having the strongest human support, but specifically from topical cosmetic studies rather than injectable Glow Protocol use; reported topical outcomes include reduced wrinkle depth and better skin density and firmness across 8 to 12 weeks. A gene-profiling analysis is also cited as finding broad GHK associations with wound-repair and inflammation-related human genes, but the source characterizes that as computational rather than direct clinical evidence. BPC-157 and TB-500 are described as remaining in the animal-data category without completed human efficacy trials. The source further states that the injected GLOW blend has no published trial of its own, so topical GHK-Cu results should not be assumed to apply to the injectable three-peptide blend. It also flags injection of copper peptides as a risk area not addressed by topical studies.	The source describes a mixed evidence base. Cell and animal work is reported for wound repair, collagen deposition, fibroblast activity, elastin and growth-factor production, keratinocyte protection, and lung-injury models. Human data are described as small topical cosmetic studies, including facial-cream and eye-cream studies with 71 and 41 participants that reported changes in skin density, thickness, and wrinkle appearance. These data are encouraging for topical skin endpoints but do not establish injected or systemic benefits.
References	Source Source +2 more Source Source	PubMed PubMed +1 more PubMed
Full profile	View Details	View Details

Save this comparison

Keep this research set handy with a free PeptiGuide account.

Save this comparison - free account

Track your peptide journey

Turn research into a private protocol log when you are ready.

Track your peptide journey

Educational use only. This information is aggregated from public research and community reports. It is not medical advice, and dosing details are descriptive, not recommendations. Always consult a qualified healthcare professional.

Property

Glow Protocol

GHK-Cu

Category

Peptide Blend

Skin & Hair

Also known as

Glow Stack, Glow Blend, Skin Rejuvenation Stack

Copper Peptide, Glycyl-L-histidyl-L-lysine copper

FDA approved

Clinical status

Preclinical Research (Components)

Pre
Preclinical
I
Phase I
II
Phase II
III
Phase III
IV
Phase IV
FDA
FDA approved

Used in cosmetic products with limited human topical-skincare evidence; the source also notes injectable compounding restrictions and a pending reclassification process.

Pre
Preclinical
I
Phase I
II
Phase II
III
Phase III
IV
Phase IV
FDA
FDA approved

What to expect

Skin rejuvenation, anti-aging, collagen production

Skin rejuvenation, wound healing, hair growth, anti-aging

How it works

Glow Protocol is described as a three-component peptide blend. GHK-Cu is the copper-binding tripeptide in the stack and is linked in the source to collagen, elastin, glycosaminoglycan production, matrix metalloproteinase modulation, and angiogenesis signals from cell and animal evidence. BPC-157 is included for proposed pro-healing and anti-inflammatory activity tied to angiogenesis and growth-factor signaling in rodent studies. TB-500 is described as an actin-binding thymosin beta-4 fragment included for cell migration and tissue-remodeling hypotheses. The source explicitly frames the combined mechanism as plausible extrapolation rather than proof that the injectable blend works as a unified product.

GHK-Cu is described as the copper(II) complex of the GHK tripeptide. The source connects its activity to copper binding and possible cellular copper delivery, but also emphasizes effects that go beyond a simple carrier model. Reported laboratory observations include shifts in gene expression, increased fibroblast production of extracellular-matrix components, keratinocyte support, vascular-related activity, and antioxidant or anti-inflammatory signals. The precise mechanism is still not fully defined.

Typical dosing

Standard vial dosing per protocol · Once daily

1-2 mg daily injection or 0.05% topical · Once daily · Subcutaneous injection or topical application

Research dosing

5:1:1 ratio GHK-Cu:TB-500:BPC-157 · 8-12 weeks for visible results · Subcutaneous injection

1-2 mg for injectable protocols · Varies by application · Subcutaneous injection or topical application

Typical duration

8-12 weeks for visible results

Varies by application

Administration

Subcutaneous injection

Subcutaneous injection or topical application

Timing

Evening

With or without food

Evening for skin or recovery contexts

With or without food

Evidence level

Preclinical

Clinical Trials

Possible side effects

Injection site reactions
Temporary skin flushing
Mild headache (Reported as rare in the source.)

+1 more

Fatigue during initial use

Generally well tolerated (Reported as a general tolerability statement in the source.)
Mild topical irritation, redness, or tingling (Associated with topical use.)
Injection-site reactions (Associated with injectable use.)

+4 more

Possible histamine release (Source advises caution for MCAS or histamine sensitivity.)
Copper toxicity risk with excessive use (Risk described for excessive exposure.)
Wilson's disease contraindication (Source lists Wilson's disease as contraindicated.)
Caution with active cancer (Source flags an angiogenesis-related concern.)

Research summary

The source distinguishes the evidence for the ingredients. GHK-Cu is described as having the strongest human support, but specifically from topical cosmetic studies rather than injectable Glow Protocol use; reported topical outcomes include reduced wrinkle depth and better skin density and firmness across 8 to 12 weeks. A gene-profiling analysis is also cited as finding broad GHK associations with wound-repair and inflammation-related human genes, but the source characterizes that as computational rather than direct clinical evidence. BPC-157 and TB-500 are described as remaining in the animal-data category without completed human efficacy trials. The source further states that the injected GLOW blend has no published trial of its own, so topical GHK-Cu results should not be assumed to apply to the injectable three-peptide blend. It also flags injection of copper peptides as a risk area not addressed by topical studies.

The source describes a mixed evidence base. Cell and animal work is reported for wound repair, collagen deposition, fibroblast activity, elastin and growth-factor production, keratinocyte protection, and lung-injury models. Human data are described as small topical cosmetic studies, including facial-cream and eye-cream studies with 71 and 41 participants that reported changes in skin density, thickness, and wrinkle appearance. These data are encouraging for topical skin endpoints but do not establish injected or systemic benefits.

References

+2 more

+1 more

Full profile